Changing costs and the impact on RSV prophylaxis

Figures & data

Table 1.  Costs of RSV prophylaxis and treatment.

Item	2007 value (CAN$)	2010 value (CAN$)	Change (%)
50 mg vial palivizumab	734	752	3
100 mg vial palivizumab	1,468	1,505	3
Paediatric ward (per diem)	957	993	4
Paediatric ICU (per diem)	2,335	2,422	4
General ward (per diem)	799	1,037	30
GP office visit	31	32	5
Paediatrics consultation	142	165	16
Community care contact	42	42	0

Table 2.  Cost effectiveness of palivizumab prophylaxis.

Analysis	2007 ICER/QALY (CAN$)	2010 ICER/QALY (CAN$)
Base case
Direct medical costs, including asthma	20,924	20,814
Direct medical costs, excluding asthma	30,618	31,360
Select sensitivity analyses
Mortality rate – Joffe et al. (1.2%)	48,751	48,495
Mortality rate – IMpact-RSV (1.0%)	50,701	50,434
Number of risk factors
Zero risk factors	801,297	820,701
One risk factors	143,267	146,218
Two risk factors	81,331	82,732
Three risk factors	26,667	26,701
Four or more risk factors	808	192
Risk-scoring tool10
Low risk (score of 0–48)	179,669	183,561
Moderate risk (score of 49–64)	34,215	34,438
High risk (score of 65–100)	5765	5274

ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.

Sampalis JS, Langley J, Carbonell-Estrany X, et al. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 2008;28:471-480

 PubMed Web of Science ®Google Scholar